Drugs / DALMITAMIG
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04626635 | Dec 2020 → Nov 2026 expected | cancer | Regeneron Pharmaceuticals | Active not recruiting | No outcome recorded |
| Phase 24 trials | ||||||
| Phase 2 | NCT07281768 | Jul 2026 → Jul 2030 expected | colorectal cancer | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Recruiting | No outcome recorded |
| Phase 2 | NCT07058012 | Apr 2026 → Apr 2029 expected | colorectal cancer | NSABP Foundation Inc | Recruiting | No outcome recorded |
| Phase 2 | NCT07154290 | Mar 2026 → Jun 2030 expected | non-small cell lung carcinoma | Regeneron Pharmaceuticals | Recruiting | No outcome recorded |
| Phase 2 | NCT06465329 | Nov 2024 → May 2027 expected | non-small cell lung carcinoma | Regeneron Pharmaceuticals | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2024-05-23 | Regeneron Pharmaceuticals | Results Promising Anti-tumor Activity of Novel Costimulatory Bispecific Antibody REGN7075 (EGFRxCD28) in Combination with Libtayo® (cemiplimab) to be Reported at ASCO regeneron.com ↗
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced positive new results from an ongoing Phase 1/2 trial evaluating its first-in-class costimulatory bispecific antibody, REGN7075 (EGFRxCD28), in combination with Libtayo® (cemiplimab) in patients with advanced solid tumors. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2024-05-23 | Regeneron Pharmaceuticals | Promising Anti-tumor Activity of Novel Costimulatory Bispecific Antibody REGN7075 (EGFRxCD28) in Combination with Libtayo® (cemiplimab) to be Reported at ASCO regeneron.com ↗ |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DALMITAMIG | ChEMBL registry synonym — accepted as the source's own label CHEMBL6068437 ↗ |
| Known as | Marlotamig | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07154290 ↗ |
| Known as | REGN7075 | “Cemiplimab 350mg + REGN7075 2700mg intravenously” NCT07058012 ↗ |
| Modality | Monoclonal antibody | — CHEMBL6068437 ↗ |
| Route | Intravenous | “Intravenous (IV) infusion or subcutaneous (SC) injection will be administered every week (QW) or every 3 weeks (Q3W)” NCT04626635 ↗ |
| Route | Subcutaneous | “Intravenous (IV) infusion or subcutaneous (SC) injection will be administered every week (QW) or every 3 weeks (Q3W)” NCT04626635 ↗ |
| Target | CD28 | “REGN7075 (EGFRxCD28 Costimulatory Bispecific Antibody)” NCT04626635 ↗ |
| Target | EGFR | “REGN7075 (EGFRxCD28 Costimulatory Bispecific Antibody)” NCT04626635 ↗ |